Blood analysis can predict kidney disease five years before damage starts

This entry passed through the Full-Text RSS service - if this is your content and you're reading it on someone else's site, please read the FAQ at http://ift.tt/jcXqJW.

Monday 09 Nov 2015 - 18:56 Makkah mean time-27-1-1437 Chicago, (IINA) - A new medical study found that testing blood for soluble urokinase-type plasminogen activator receptor (suPAR) can predict a patient's risk of developing chronic kidney disease (CKD) as early as five years before damage from the condition is seen, UPI reported. Researchers compare finding the significance of suPAR to discovering the role that testing cholesterol levels now plays in diagnosing cardiovascular disease. CKD affects more than 15 percent of people in the United States and causes about 47,000 deaths per year. Most people do not know they have it until the disease is advanced. The symptoms of CKD, such as blood in the urine, swollen hands and feet, and excessive thirst, do not usually show up until severe damage has been done to organs. The two markers used for CKD, measuring creatinine levels in the blood and protein levels in urine, can help doctors monitor the condition, but they are not sensitive enough to catch the disease early or predict risk for its development. "The observation that high suPAR levels predict the future development of chronic kidney disease in different populations suggests this molecule may be a target for treatment to improve clinical outcomes in the majority of patients at risk for future kidney disease", said Dr. Howard Trachtman, a pediatric nephrologist at NYU Langone Medical Center. "Blocking suPAR may prove to be comparable in its application to the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers which are among the few drugs approved for treatment of chronic kidney disease". While suPAR levels alone can show the risk of developing CKD, researchers said other risk factors must be explored, and more research with larger and more diverse groups of patients will be needed to refine the test for common use. AG/IINA